Pharmacological Topics of Bone Metabolism: Antiresorptive Microbial Compounds That Inhibit Osteoclast Differentiation, Function, and Survival

Woo, Je Tae; Yonezawa, Takayuki; Yoon, Byung; Teruya, Toshiaki; Nagai, Kazuo

doi:10.1254/jphs.fm0070288

Cited by 26 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It integrates into osteoclasts and kills them. Its inhibitory effect on bone resorption was observed in animal studies [147] as well as in vitro studies [148]. It seems that reveromycin A will be a novel antiresorptive agent in future.…”

Section: Igfsmentioning

confidence: 89%

Current, new and future treatments of osteoporosis

2010

View full text Add to dashboard Cite

Osteoporosis as a common chronic disease is challenging human health. Although different therapeutic options are routinely used for prevention/treatment of osteoporosis, their side effects and benefits are under question. Increasing our knowledge about signaling pathways in bone and osteocytes as well as osteoblasts and osteoclasts will help us in designing new therapeutic modalities for osteoporosis. In the present study, all new therapeutic measures of osteoporosis have been reviewed. For this purpose, search engines like Pubmed, Web of Science, Scopus, Google Scholar were searched and all relevant articles were found. The study was limited to the year 1998-2010. Bisphosphonates are the cornerstone of osteoporosis treatment, but there are not enough relevant studies that investigated their equivalencies in comparison with each other or the other medications. Therefore, medication selection is empirical and subjective. Furthermore, no eminent study has compared certain combinations. There are new hopes for treatment of osteoporosis, which are more specific with less harm. Our results show that new and emerging therapies are more potent and target specified which more individualize osteoporosis treatment; however, more investigations on their safety and efficacy in comparison with current medications are highly recommended.

show abstract

Section: Igfsmentioning

confidence: 89%

Current, new and future treatments of osteoporosis

2010

View full text Add to dashboard Cite

show abstract

“…Statins are known to upregulate BMP‐2 expression (Mundy et al, ) and promote osteoblast differentiation and mineralization (Maeda et al, ). In addition, it has been reported that statins also inhibit the formation and activity of osteoclasts (Hughes et al, ; Jeon et al, ; Woo et al, ) by reducing the expression of the osteoclastic enzyme cathepsin K. Thus, statins play an important role in both osteoblast activation and osteoclast inhibition, which leads to increased bone mass.…”

Section: Discussionmentioning

confidence: 99%

Discontinuation of simvastatin leads to a rebound phenomenon and results in immediate peri‐implant bone loss

Zhang

et al. 2016

Clinical & Exp Dental Res

View full text Add to dashboard Cite

Although administration of simvastatin has been reported to promote bone formation, the effect of short‐term simvastatin administration is not well known. Following implant installation, 10‐week‐old male Wistar rats (n = 24) were divided into two groups randomly. The experimental group received 10 mg/kg of simvastatin daily for seven days. Then simvastatin administration was discontinued, and the animals were observed up to 28 days. Animals in the control group underwent the same procedure but received saline instead of simvastatin. All animals were analyzed by micro‐computed tomography. Samples at days 14 and 21 were subjected to histological analyses. After seven days of simvastatin administration, more new bone formation around the implant was observed in the simvastatin group compared with the control group. Seven days after simvastatin discontinuation, however, the amount of peri‐implant trabecular bone began to decrease. Results from morphometric analysis also showed a reduction in new bone area after day 7, which was lowest at day 14. These results were confirmed by histological analyses. In contrast, both the peri‐implant trabecular bone and new bone area were maintained in the control group. Short‐term administration of simvastatin may affect implant stability owing to a rebound phenomenon and an immediate loss of peri‐implant bone.

show abstract

“…Accordingly, many data show the importance of IL-6 in the development of chronic inflammatory-associated diseases (particularly rheumatoid arthritis and inflammatory bowel disease) [23,24] as well as post-menopausal osteoporosis. In particular, it is well established that circulating levels of IL-6 display an age-associated increase [25]; moreover, both human and animal studies suggest that bone loss associated with the menopause may be linked to activation of osteoclasts by IL-6, as a consequence of the removal of the strong inhibitory activity of estrogens upon the production of this cytokine by osteoblasts [26].…”

Section: Discussionmentioning

confidence: 99%